Shots:

• The EUA was based on P-II BLAZE-4 trial assessing bebtelovimab (175 mg) alone or together with bamlanivimab (700mg) and etesevimab (1400mg) in non-hospitalized patients with mild-to-moderate COVID-19 
• Pseudovirus and authentic virus testing showed that bebtelovimab retains full neutralizing activity against Omicron. Additionally, pseudovirus testing unveiled that it retains neutralization against all other known variants of interest and concern, including BA.2
• Lilly will supply up to 600,000 doses of investigational drug bebtelovimab for at least $720M, as per the agreement signed with the US government

 Ref: Lilly | Image: Wall Street Journal